Long-form reporting on peptide science.
How these compounds came to be studied: the laboratories, the accidents, the arguments and the long gaps between a promising finding and a settled one.
Latest articles
How Oxytocin Became the Love Hormone
A nine-amino-acid hormone of childbirth, two species of vole, one famous nasal-spray experiment and a bestselling book. How a molecule acquired a reputation, and what happened when other scientists went back to check it.
The Antibiotic That Sat in a Drawer for Six Years
A large company walked away from a promising molecule after a muscle signal and a disappointing dosing schedule. A small one with no products picked it up in 1997 and found that the schedule, not the molecule, had been the problem.
The Brown Liquid They Called Mississippi Mud
A parcel of soil from a Borneo forest reached a pharmaceutical laboratory in Indiana in the early 1950s. Within a few years it had become the antibiotic hospitals still keep for when almost everything else fails. The path between the two was stranger than the drug.
The Contaminant That Became a Hormone
In 1923 the new insulin extracts did something their makers did not want: they briefly raised blood sugar. It took thirty years to crystallise the culprit, and sixty to see why it matters to the newest generation of metabolic drugs.
The Experiment That Named the Hormone
In January 1902 two physiologists at University College London cut every nerve to a dog's gut and still watched the pancreas respond. What they concluded forced a new word into the language, and a libel trial, a riot and a statue followed.
The Free Samples That Cost $875 Million
A peptide analogue for advanced prostate cancer made a joint venture rich, and then made it the subject of what the Justice Department called the largest criminal fine in a health care fraud case. The story is about arithmetic: a list price nobody paid, and a box of samples with an invoice attached.
The Greek Chemist and the Group That Came Off Clean
In 1932 a young chemist from the Peloponnese helped solve the problem that had stopped Emil Fischer. The protecting group he co-invented shaped peptide chemistry for three decades, and the school he built in Athens carried the work into the age of insulin.
The Guideline That Took Four Years to Write
A European medicines document with a long reference number became the rule on 1 June 2026. The story of why it was needed, how it was drafted in public, and the boundary it quietly draws around everything else.
The Hormone Harvested From the Dead
For twenty-seven years, from the first report in 1958, growth hormone for children came from human pituitary glands collected at autopsy. What ended the programme in 1985, what replaced it within months, and why the story is not quite finished.
The Hormone That Was Supposed to Cure Autism
In 1998 a 1902 digestive hormone became, for a few months, the most talked-about idea in the autism community. The anatomy of a claim: a small report, a television programme, a shortage, the trials that followed, and the review that closed the file.
The Machine That Read a Protein One Letter at a Time
A Swedish chemist devised a reaction in 1950 that peeled one amino acid at a time from a chain. Seventeen years later, in a Melbourne hospital laboratory, he and a colleague built a machine to do it unattended. It ruled protein chemistry for two decades, then was overtaken.
The Man Who Proved a Protein Had a Spelling
Before 1955 nobody knew whether a protein was a definite molecule or a family of loosely similar ones. Frederick Sanger settled it for insulin with a yellow reagent, sheets of filter paper and a patience that took the best part of a decade.
The Peptide in the Cheese: A Century of Nisin
It began as a nuisance in a dairy culture in 1928. It is now a code on an ingredients list, E234, eaten by millions who have never heard of it. The history of nisin is the history of a peptide antibiotic that became a food ingredient instead of a medicine.
The Peptide That Needed Its Own Factory
Enfuvirtide, a 36-residue piece of a viral protein, was approved in 2003 as the first drug of its kind. Making it required a purpose-built plant, a process of more than a hundred steps, and a price that drew protest from the people who needed it most.
The Prague Institute That Redesigned a Hormone
In 1967 chemists at a Czechoslovak institute made two small changes to a nine-residue hormone and produced a molecule that kept one of its jobs and largely dropped the other. It became one of the best-known peptide drugs in the world, and it came from the wrong side of the Iron Curtain.
The Receptor That Waited Twenty Years for Its Hormone
Most drugs are built to imitate something nature already made. In this case the imitation came first: a laboratory peptide, then its receptor, then, more than two decades after the first clue, the hormone the receptor had been waiting for. A discovery story told back to front.
The San Diego Company That Got There First
Amylin Pharmaceuticals was founded on a hormone found in the wrecked pancreases of diabetic patients, nearly died in 1998, launched two first-in-class peptide medicines in the spring of 2005, and was sold in 2012. The first mover did not become the winner.
The Soil That Was Fed Bacteria: Gramicidin, 1939
Two years before penicillin was purified, a French-born microbiologist at the Rockefeller Institute set out to find an antibiotic on purpose, by feeding dirt. What came out of the soil was the first antibiotic to reach a clinic, and it was a peptide.
The Sweetener That Waited Sixteen Years
Aspartame is a dipeptide with a methyl group on its end, found by accident in 1965 and not cleared in the United States, for dry goods, until 1981. Its regulatory history is a case study in how agencies decide, disagree and decide again.
The Two Insulin Houses of Copenhagen
For about sixty-five years one Danish city was home to two rival insulin makers, founded by a quarrel and bound together by a shared sense of mission. How they began, what they competed over, and why they ended as a single foundation-owned company.
How a Word From Biochemistry Became a Hashtag
For a century the word sat on order forms and in textbooks, naming a size of molecule and nothing more. Then it borrowed the fame of two medicines and found a medium built for words that sound exact and promise everything.
Inside a Solid-Phase Synthesiser
The invention of the method is a famous story. The working day is not. One shift at a modern synthesiser, from a weighed-out resin to the grey pellet at the bottom of a centrifuge tube, and the arithmetic that decides how much of it is worth keeping.
Natural, Synthetic, and the Marketing In Between
Two chromatograms laid one over the other, peak for peak, and no way to tell which molecule came from a living cell and which from a machine. The words on the label insist there is a difference. The molecule does not.
The Biochemist and the Blue Copper Tripeptide
A farm boy who sold his books to join the Army spent fifty years on a molecule three amino acids long. The route he took it down — thesis, wound-care company, device clearance, skincare jar — is the route most research findings take into the bathroom cabinet.
The Biohacker and the Regulator
Medicine keeps a hall of fame for people who experimented on themselves. Medicines law was never written with them in mind. In 2026 the two finally met, and the meeting took place at a clinic and a pharmacy rather than in anyone's kitchen.
The Cell That Makes the Peptide Instead
Not every peptide comes off a bead. The longer ones are often grown in steel tanks by bacteria or yeast that have been handed a gene, and pulled out of the soup afterwards. The two routes can make the same molecule — and leave very different fingerprints behind.
The Chemist Who Gave GLP-1 a Week
A hormone the body destroys within minutes had defeated a generation of drug developers. A chemical engineer at a Danish insulin company kept it alive by borrowing a trick from insulin, argued against the grain about what it was for, and shared a Lasker Award for it.
The Compounding Boom, and How It Ended
The statute was written in 2013 and the window it opened for the GLP-1 drugs closed in 2025. This is what grew inside that window, why it kept going after the window shut, and the enforcement year that finally ended it on three continents.
The Fight Over Who Pays for an Obesity Drug
On 1 July 2026 Medicare began paying for obesity medicines for the first time — not by changing the law that forbids it, but by working around it. The long argument over cost, value and fairness that led there, on both sides of the Atlantic.
The Freeze-Dryer and the Cake
The white puck at the bottom of a vial is the fossil of a three-day process: a solution frozen on a steel shelf, its ice pulled off as vapour under vacuum, its last traces of water coaxed out by gentle heat. Every feature of the cake records something about how that went.
The Grey Market That Grew in the Gap
By the summer of 2026 a drug that no regulator had approved had a retail trade, a payment system and its own testing culture. How a research-reagent market and a wellness market came to share the same sellers — and what regulators saw, and when.
The Law That Tried to Move the Factories Back
For thirty years peptide manufacturing drifted east because the arithmetic said so. In December 2025 the United States passed a law that pushes, carefully and narrowly, in the other direction. What it restricts is smaller than the headlines, and what it set in motion is larger.
The Longevity Industry and Its Favourite Molecules
The menus are printed on heavy card and the vocabulary is scrupulous: support, optimise, cellular health. The evidence behind the molecules on them is a good deal thinner than the paper, and the care taken over the words is part of the story.
The Man Who Found a Hormone in a Gland Everyone Ignored
A young biochemist helped name the thymosins in 1966, turned a calf-thymus extract into something a regulator would let near sick children, and pulled the first defined peptide out of it. The medicine it became is sold in dozens of countries — just not the one where it was found.
The Molecule That Moved a Country's GDP
For two years, most of Denmark's economic growth was the output of one industry, dominated by one company selling one class of peptide medicine. What that did to a small economy's statistics, its currency and its public finances — and what happened when the company stumbled.
The Moscow Institute That Made Peptides for the Mind
Two Russian peptides now come up for debate before American regulators. They were built in the 1980s at a Moscow institute that took an idea from a Dutch pharmacologist, fixed its fatal flaw with three amino acids, and then spent decades working out why its own medicines did what they did.
The Patent Cliff and the First Generic Peptide Blockbuster
On 20 March 2026 the compound patent on semaglutide expired in India, China and Brazil, months after it had quietly lapsed in Canada. For the first time a best-selling peptide medicine began to go generic — country by country, and on no common timetable.
The Purification Nobody Sees
A synthesiser makes a crowd of near-identical chains. A steel column the width of a drainpipe, a rack of collection tubes and a chemist with a spreadsheet decide which of them becomes the product — and how much of the batch is thrown away to get there.
The Scientist Whose Name Came Late
In the 1980s a peptide chemist in Boston worked out which fragment of a newly read gene was the real hormone. Her name then went missing from the patents, the retellings and the prizes, and it took her the better part of three decades to put it back.
When an Athlete Tests Positive for a Peptide
A urine sample collected at a rugby league training ground in December 2014 was analysed, found clean and put into storage. Six years later somebody took it out again. What a peptide case proves, and how often one begins without a positive test at all.
How Peptide Manufacturing Moved East
The invention of solid-phase synthesis is told often, usually as a story about elegance. The industrialisation of it is almost never told at all — and it explains far more about what is on the market today.
The Cold Chain Nobody Built for Research
The world's first large temperature-controlled logistics network was assembled in the 1970s to get vaccines to villages with no electricity. Everything shipped cold since has been riding on rails laid for something else.
The Counterfeit Problem Is Older Than the Internet
Two centuries before anyone shipped a vial from a website, a German chemist in London opened a bottle of pickles and found copper. The history of fake medicine is the history of the instruments that could finally see it.
The Price of a Gram Over Sixty Years
In 1953 the cost of a peptide was quoted in careers. By the 2010s it was quoted in fractions of a currency unit per milligram. The story of how that happened is four step changes and one stubborn exception.
The Shortage Years
Between 2022 and 2025 the best-selling drugs in the world could not be made fast enough. The constraint was almost never the peptide — it was the machinery that puts a liquid into a device, and that turned out to be the hardest thing in the industry to buy.
How a Substance Becomes a Controlled One
A molecule can be entirely lawful on a Monday and a scheduled substance by Thursday, with no new experiment performed in between. Scheduling is an administrative act, and understanding it as an act rather than a finding explains almost everything about how the lists behave.
The Category Nobody Designed
Four words on a label — For Research Use Only — now carry an enormous amount of weight in a market their authors never imagined. They were written in the 1970s to solve a narrow problem about diagnostic test kits, and they have never been rewritten.
The Compounding Pharmacy Question
Making a medicine to order is the oldest thing a pharmacist does, and for most of history it was the only thing. How that ancient practice acquired a modern statute — written in 2013, after an outbreak that killed more than sixty people — and what happened when it met a national shortage of the best-selling drugs on earth.
The Elixir That Wrote the Drug Law
In September 1937 a Tennessee company dissolved a new wonder drug in something very close to antifreeze and shipped it across America. More than a hundred people died, and no law had been broken. Almost everything about how medicines are approved today was assembled afterwards, out of the wreckage.
When a Regulator Names a Product
On 8 July 2026 the Greek medicines agency published a notice about intravenous preparations being sold as food supplements. It made the evening news. Understanding what such a notice is — and, more importantly, what it is not — is one of the more useful literacies available in this field.
The Chemist Who Named the Bond
Before anyone could build a peptide, somebody had to decide that proteins were chains, that the links were all the same kind of link, and what to call them. Emil Fischer spent the last twenty years of his life proving it, one laborious dipeptide at a time.
The Hormone Found by Looking for Something Else
For years two laboratories hunted the brain signal that tells the pituitary to release growth hormone. What kept turning up instead was a signal telling it to stop — and the wrong answer became a diagnostic tool, then a drug class, then a whole receptor family.
The Longest Chain Anyone Had Built
Thirty-nine amino acids does not sound like much now. In the middle of the 1950s it was a wall — and the way round it turned out to be the discovery that most of the molecule did not matter.
The Nine Amino Acids That Won a Nobel
In 1953 a laboratory on the East Side of Manhattan worked out the order of nine amino acids in a pituitary hormone, built that order from bottled chemicals, and found the result behaved exactly like the real thing. Everything the field has done since walks out of that room.
The Three-Way Race to Make Insulin
By the end of 1963 three laboratories on three continents were building the same protein from bottled chemicals, and none of them could agree on who had finished. What they were really testing was whether a protein could be made at all.
The Column That Separated Everything
A Russian-Italian botanist poured a leaf extract through a tube of powdered chalk and watched it split into coloured bands. A century later, the same idea decides whether a peptide can be called pure.
The Crystal and the Beam
In 1935 a young researcher in Oxford took an X-ray photograph of an insulin crystal and saw that it was ordered enough to be solved. It took another thirty-four years to solve it.
The Machine That Learned to Weigh a Molecule
To weigh a molecule you first have to get it airborne and give it a charge. For most of the twentieth century, doing that to a protein simply destroyed it — until a chemist in his sixties started spraying them out of a needle.
The Microscope That Had to Be Frozen
An electron microscope destroys biological material while it looks at it, and the vacuum it works in boils away the water any protein needs. Cryo-EM is the long story of getting around both problems at once.
The Prediction That Outran the Experiment
For twenty-five years a blind competition asked whether anyone could predict a protein's shape from its sequence, and for twenty-five years the answer was: a little, sometimes. Then one entry stopped being wrong.
What Is Actually in the Vial
A label is a claim, and for most of this market nobody independent has ever checked it. A handful of analytical chemists have — and what they found is a different problem from the one everyone argues about.
The Other Peptide Tradition
In Russia these are registered medicines with decades of published work behind them; in Britain most doctors have never heard of them. The gap between those two facts is not a verdict on the science — and that turns out to be much harder to live with than one.
How Skincare Borrowed the Word Peptide
The word is on jars at every price, almost never with a concentration, a study or a specific molecule attached. What it is doing there turns out to be a question about law as much as about chemistry.
From a Million Brains to a Usable Drug
Somatostatin was pulled out of the hypothalamus in 1973, did exactly what had been promised of it, and vanished from the bloodstream in about two minutes. Turning that result into a medicine meant throwing most of the molecule away.
Why So Many Drugs Come Out of Venom
A snake, a sea snail and a desert lizard have each handed medicine a drug class. That is not a run of luck — it is what happens when you raid a chemistry programme that has been running for tens of millions of years.
The Assay That Made Hormones Visible
Before 1959, a hormone in a living person was something you could reason about but never weigh. Then a physicist and a physician in a Bronx veterans' hospital turned an inconvenient antibody into the most sensitive measuring device biology had ever had.
The Hunt for the Hormones That Command the Pituitary
To find the molecules by which the brain gives orders to the endocrine system, two rival laboratories spent twenty years reducing animal brains by the tonne to a residue you could barely see. The first answer they got back was three amino acids long.
The Decades When Peptides Fell Out of Fashion
For roughly twenty years the pharmaceutical industry held a class of molecules that had already given medicine insulin — and largely walked away from it. Nothing about that decision was foolish, which is exactly what makes the return worth explaining.
The Hundred-Year Problem of Swallowing a Peptide
From the moment insulin existed, someone asked whether it could be a tablet, and for the better part of a century the answer was a flat no. The story of how that no was finally, partially, expensively overturned.
Why the Claims Outrun the Evidence
A compound can gather a couple of hundred papers reporting benefit and still have never been given to a single person under controlled conditions. The distance between those two facts is not the work of liars — it is built into the way findings travel.
The Genome Everyone Thought Was Finished
The human mitochondrial genome was sequenced in 1981, catalogued at thirteen proteins, and filed away as complete. It was hiding genes — and they were found not by reading the sequence but by tripping over what they did.
Testing for a Molecule the Body Already Makes
Anti-doping chemistry usually asks a simple question: is this foreign substance here or not? Peptides refuse to answer it, because most of them are not foreign at all.
The Year the Obesity Drugs Worked
For half a century, obesity pharmacology was where careful people went to be disappointed. Then a trial reported a number that belonged, until that moment, to the operating theatre.
Thymosin and the Gland It Was Named For
A peptide was named in the 1960s for the organ it came out of and the effect that organ was thought to have. Both halves of the name turned out to be wrong, and neither correction ever reached the label.
The Blood of Young Donors and a Tripeptide
Liver cells kept their character longer when the serum bathing them came from a young donor. Finding out why produced one of the smallest molecules in active research — and a fifty-year literature with one name running through it.
The Zagreb School and a Literature With One Centre
Several hundred papers report that one short peptide accelerates repair in almost every tissue it has been tested on. Nearly all of them trace back to a single university programme — which is the most interesting thing about the whole affair.
The Arizona Lab and the Drug That Escaped
One university programme in the Sonoran Desert set out to invent a tan you could get without the sun. It ended up producing both a licensed prescription medicine and one of the most widely misused unlicensed peptides in circulation.
The Machine That Made Peptides Cheap
For a chemist in the 1950s, assembling a chain of nine amino acids was the work of years and worth a Nobel Prize. Then Bruce Merrifield fixed his molecule to a plastic bead, and the arithmetic of an entire field changed.
How Insulin Changed What a Drug Could Be
A hundred years ago a protein went into a dying boy's arm and came out the other side as a medicine. Almost everything peptide science has done since walked through that door.
The Gila Monster and the GLP-1 Drugs
A venomous lizard in the deserts of the American Southwest had already solved the problem that stalled a decade of pharmaceutical chemistry. It took an endocrinologist working on a side interest to notice.